Circulating osteocalcin during oral anticoagulant therapy.
In this paper we present the following observations: 1) In sheep vitamin K-antagonists like phenprocoumon induce a decrease of the serum levels of osteocalcin (bone Gla-protein) and of the affinity of the circulating osteocalcin for hydroxyapatite. 2) In sheep vitamin K counteracts the effect of phenprocoumon on the blood coagulation system, but not that on the osteocalcin production. 3) In human subjects vitamin K-antagonists also lead to decreased levels of serum osteocalcin and a low affinity of the protein for hydroxyapatite. 4) These two variables reached steady-state levels within 24 h after the start of oral anticoagulant treatment and--at continuation of the therapy--they remained low for at least several years.
van Haarlem
L J
LJ
Department of Biochemistry, University of Limburg, Maastricht, The Netherlands.
Knapen
M H
MH
Hamulyák
K
K
Vermeer
C
C
D000074:Acenocoumarol / Q000494:pharmacology; D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage / Q000494:pharmacology*; D002135:Calcium-Binding Proteins / Q000097:blood*; D006801:Humans; D015675:Osteocalcin; D010644:Phenprocoumon / Q000494:pharmacology; D012756:Sheep; D014812:Vitamin K / Q000494:pharmacology*
D000925:Anticoagulants; D002135:Calcium-Binding Proteins; D015675:Osteocalcin; D014812:Vitamin K; D000074:Acenocoumarol; D010644:Phenprocoumon